Literature DB >> 2055603

C1 inhibitor: different mechanisms of reaction with complement component C1 and C1s.

G L Hortin1, B L Trimpe.   

Abstract

Inactivation of human complement subcomponent C1-s by its regulator C1 inhibitor at physiological ionic strength proceeded at a 3-fold higher rate when C1-s was in the physiological C1- complex with subcomponents C1q and C1-r rather than as purified subunit. When the C1- complex was disassembled by chelation of calcium, the C1-s subcomponent was inactivated by C1 inhibitor at rates similar to those for the purified proteinase. Increasing ionic strength had little effect on the reaction of purified C1-s with C1 inhibitor but greatly diminished the rate of reaction of intact C1-. Addition of heparin accelerated the inactivation of purified C1-s by C1 inhibitor up to 25-fold but increased the inactivation of intact C1- only about 5-fold. These differences in the inactivation of C1-s by C1 inhibitor, depending on whether the proteinase is free or complexed with other subcomponents of C1-, suggest different mechanisms of reaction. Occurrence of subcomponent C1-s in a macromolecular complex with C1q and C1-r, thus, appears to be critical not only for directing its physiological activation but also its inactivation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2055603     DOI: 10.3109/08820139109054926

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  2 in total

1.  Influence of the electric charge of the antigen and the immune complex (IC) lattice on the IC activation of human complement.

Authors:  M A Michelin; L S P Crott; A I Assis-Pandochi; T M Coimbra; J E Teixeira; J E Barbosa
Journal:  Int J Exp Pathol       Date:  2002-04       Impact factor: 1.925

2.  Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.

Authors:  E Eldering; C C Huijbregts; J H Nuijens; A J Verhoeven; C E Hack
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.